Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/43098
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3391]
Metadata
Show full item record
CHARACTERISTICS OF REPRIEVE TRIAL PARTICIPANTS IDENTIFYING ACROSS THE TRANSGENDER SPECTRUM
Author
Smeaton, Laura M.
Kileel, Emma M.
Grinsztejn, Beatriz
Gardner, Edward M.
Starr, Kate
Murry, Melissa L.
Desvigne-Nickens, Patrice
Alston-Smith, Beverly
Waclawiw, Myron A.
Cooper-Arnold, Katharine
Madruga, José V.
Sangle, Shashi
Fitch, Kathleen V.
Zanni, Markella V.
Douglas, Pamela S.
Ribaudo, Heather J.
Grinspoon, Steven K.
Klingman, Karin L.
Kileel, Emma M.
Grinsztejn, Beatriz
Gardner, Edward M.
Starr, Kate
Murry, Melissa L.
Desvigne-Nickens, Patrice
Alston-Smith, Beverly
Waclawiw, Myron A.
Cooper-Arnold, Katharine
Madruga, José V.
Sangle, Shashi
Fitch, Kathleen V.
Zanni, Markella V.
Douglas, Pamela S.
Ribaudo, Heather J.
Grinspoon, Steven K.
Klingman, Karin L.
Affilliation
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA.
Massachusetts General Hospital and Harvard Medical School. Metabolism Unit. Boston, Massachusetts, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Denver Public Health. Denver, Colorado, USA.
The Ohio State University. Columbus, Ohio, USA.
Houston Cross Network Community Advisory Board. Houston, Texas, USA.
National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland, USA.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Bethesda, Maryland, USA.
National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland, USA.
National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland, USA.
Centro de Referencia e Treinamento DST/AIDS. São Paulo, SP, Brasil.
BJ Medical College. Department of Medicine. Pune, India.
Massachusetts General Hospital and Harvard Medical School. Metabolism Unit. Boston, Massachusetts, USA.
Massachusetts General Hospital and Harvard Medical School. Metabolism Unit. Boston, Massachusetts, USA.
Duke University School of Medicine. Duke Clinical Research Institute. Durham, North Carolina, USA.
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA.
Massachusetts General Hospital and Harvard Medical School. Metabolism Unit. Boston, Massachusetts, USA.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Bethesda, Maryland, USA.
Massachusetts General Hospital and Harvard Medical School. Metabolism Unit. Boston, Massachusetts, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Denver Public Health. Denver, Colorado, USA.
The Ohio State University. Columbus, Ohio, USA.
Houston Cross Network Community Advisory Board. Houston, Texas, USA.
National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland, USA.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Bethesda, Maryland, USA.
National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland, USA.
National Institutes of Health. National Heart, Lung, and Blood Institute. Bethesda, Maryland, USA.
Centro de Referencia e Treinamento DST/AIDS. São Paulo, SP, Brasil.
BJ Medical College. Department of Medicine. Pune, India.
Massachusetts General Hospital and Harvard Medical School. Metabolism Unit. Boston, Massachusetts, USA.
Massachusetts General Hospital and Harvard Medical School. Metabolism Unit. Boston, Massachusetts, USA.
Duke University School of Medicine. Duke Clinical Research Institute. Durham, North Carolina, USA.
Harvard T. H. Chan School of Public Health. Center for Biostatistics in AIDS Research. Boston, Massachusetts, USA.
Massachusetts General Hospital and Harvard Medical School. Metabolism Unit. Boston, Massachusetts, USA.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Bethesda, Maryland, USA.
Abstract
Because persons who identify across the transgender spectrum (PATS) are a key population in human immunodeficiency virus (HIV) yet are underreported in HIV and cardiovascular research, we aimed to characterize this population within the REPRIEVE global clinical trial (n = 7770). Acceptance of gathering gender identity was high (96%). Participation by PATS was 1.7% overall, 2.4% among natal males, 0.3% among natal females, and varied across geographic regions (from 0% in sub-Saharan Africa to 2.3% in High Income Region). Thirty percent of natal male PATS identified other than transgender. Some characteristics differed by gender. Most notably, 38% of natal male PATS receiving gender-affirming treatment had waist circumference >102 cm (compared with ≤25% in other groups). Given that PATS is a key population, HIV research should routinely report trial participation and outcomes by gender in addition to natal sex, to provide the results needed to optimize medical care to PATS.
Share